Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase 2a/2b study of LY3541860 versus placebo in adults with relapsing multiple sclerosis
MOH_2024-05-30_013451Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing LY3541860 800 mg every 4 weeks with Placebo then LY3541860 200 mg every 4 weeks (2 arms). Primary endpoint: Occurrence of new gadolinium-enhancing T1 lesions. Started May 2024; status: recruiting.
02
Drugs
LY3541860
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2024-05-30_013451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-30_013451.